Halozyme Therapeutics | HALO - Operating Profit


Halozyme Therapeutics reported $-61.77M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD -4.62M 22.01M Mar/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
Amarin USD -2.26M 564K Dec/2025
Amgen USD 3.83B 130M Mar/2026
Baxter International USD 66M 280.2M Mar/2026
Cara Therapeutics USD -5.94M 3.55M Sep/2025
Cytokinetics USD -181.23M 2.86M Mar/2026
DBV Technologies USD -34.28M 6.83M Sep/2025
Eli Lilly USD 9.78B 792M Mar/2026
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
Halozyme Therapeutics USD -61.77M 26.64M Mar/2026
Intrexon USD -60.84M 26.62M Jun/2024
Ionis Pharmaceuticals USD -118M 97M Mar/2026
MannKind USD -76.99M 7.75M Mar/2026
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Pfizer USD 4.99B 340M Mar/2026
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
United Therapeutics USD 325.8M 340.4M Mar/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024